2025 Q4
2025-10-21
Q3 Earnings
Q3 2025 financial results for quarter ended Sep 30, 2025
View Filing →
2025 Q3
2025-07-22
Q2 2025 Earnings
Q2 2025 financial results announced
View Filing →
2025 Q2
2025-05-15
CEO Transition
David Rosa appointed CEO July 1, Gary Guthart becomes Executive Chair
View Filing →
2025-05-05
Annual Meeting & Share Buyback
$4.0B share repurchase authorized, 5M shares added to incentive plan
View Filing →
2025-04-22
Q1 2025 Earnings
Q1 2025 financial results announced
View Filing →
2025 Q1
2025-01-23
Q4 Earnings + Acquired EU Distribution
€290M upfront + €31M milestones for EU distributors
View Filing →
2025-01-15
Q4 2024 Earnings
Preliminary Q4 and full year 2024 results announced
View Filing →
2025-01-06
CFO and CCO Promotions
Samath salary $605K→$683K, Charlton $600K→$670K, both bonus targets 65%→100%
View Filing →
2024 Q4
2024-10-17
Q3 2024 Earnings
Q3 2024 financial results announced
View Filing →
2024 Q3
2024-07-25
Board Appointment
David J. Rosa appointed to Board, size increased to 12 members
View Filing →
2024-07-18
Q2 2024 Earnings
Financial results for quarter ended June 30, 2024
View Filing →
2024 Q2
2024-04-30
Annual Shareholder Meeting Results
All 11 directors elected, pay equity proposal rejected
View Filing →
2024-04-18
Q1 2024 Earnings
Q1 2024 financial results announced
View Filing →
2024 Q1
2024-03-14
FDA Clears da Vinci 5 System
Fifth-generation robotic surgical system approved
View Filing →
2024-01-23
Q4 2023 Earnings
Financial results for quarter ended December 31, 2023
View Filing →
2024-01-09
Q4 2023 Preliminary Results
Preliminary Q4 and full year 2023 financial results announced
View Filing →
2023 Q4
2023-10-31
Board Appointment
Sreelakshmi Kolli appointed to Board, increased to 12 members
View Filing →
2023-10-19
Q3 2023 Earnings
Financial results for quarter ended September 30, 2023
View Filing →